Martin S E, Moshiri S, Thor A, Vilasi V, Chu E W, Schlom J
Am J Clin Pathol. 1986 Jul;86(1):10-8. doi: 10.1093/ajcp/86.1.10.
Metastatic adenocarcinoma in human effusions can be difficult to distinguish from reactive mesothelial cells, particularly if the malignant cells are rare, have bland cytologic features, or occur as single cells rather than clusters of cells. Monoclonal antibody (MAb) B72.3, generated against a membrane-enriched fraction of breast carcinoma, has been shown to be reactive with formalin-fixed, paraffin-embedded tissue sections of human breast and colon carcinomas but not with sarcomas, melanomas, hematopoietic neoplasms, or a variety of normal adult tissues. The authors have adapted the avidin-biotin-immunoperoxidase method using MAb B72.3 to evaluate cytospin preparations of pleural and peritoneal effusions for the presence of adenocarcinoma cells. The cytospin method was selected because it provides a rapid, efficient, and inexpensive means of evaluating effusions for cellular content. Reactive effusions from patients with no history of adenocarcinoma as well as obviously malignant effusions from patients with documented adenocarcinoma were studied. MAb B72.3 demonstrated no reactivity with any of the variety of cell types in the reactive specimens from patients without a history of adenocarcinoma. In contrast, in all of the malignant effusions studied, 10-90% of the nonhematopoietic cells demonstrated reactivity with MAb B72.3. In addition, MAb B72.3 highlighted occult adenocarcinoma cells in cytospin preparations of effusion fluids from patients with a primary diagnosis of adenocarcinoma in which no definite malignant cells could be identified using standard cytologic criteria.
人胸腹水转移性腺癌可能难以与反应性间皮细胞区分开来,尤其是当恶性细胞稀少、具有平淡的细胞学特征或以单个细胞而非细胞簇形式出现时。针对乳腺癌富含膜成分产生的单克隆抗体(MAb)B72.3,已显示与人乳腺癌和结肠癌的福尔马林固定、石蜡包埋组织切片有反应,但与肉瘤、黑色素瘤、造血系统肿瘤或多种正常成人组织无反应。作者采用抗生物素蛋白-生物素-免疫过氧化物酶法,使用MAb B72.3评估胸腔和腹腔积液的细胞离心涂片制备物中是否存在腺癌细胞。选择细胞离心涂片法是因为它提供了一种快速、高效且廉价的评估积液细胞成分的方法。研究了无腺癌病史患者的反应性积液以及有记录的腺癌患者的明显恶性积液。MAb B72.3对无腺癌病史患者反应性标本中的任何细胞类型均无反应。相比之下,在所有研究的恶性积液中,10% - 90%的非造血细胞与MAb B72.3有反应。此外,MAb B72.3突显了原发性诊断为腺癌患者的积液细胞离心涂片制备物中的隐匿腺癌细胞,而这些患者使用标准细胞学标准无法识别明确的恶性细胞。